Skip to main content
. 2020 Dec 3;10(1):74–87. doi: 10.12997/jla.2021.10.1.74

Table 2. Hazard ratios of mortality, myocardial infarction, and stroke by HDL-C categories in men.

HDL-C categories Subjects Event Incidence rate* Hazard ratio (95% confidence interval)
Model 1 Model 2 Model 3
All-cause mortality
<30 1,817 147 14.3 2.42 (2.04–2.86) 1.99 (1.68–2.36) 1.86 (1.57–2.21)
30–39 22,010 943 7.6 1.28 (1.18–1.38) 1.24 (1.14–1.34) 1.18 (1.09–1.28)
40–49 56,703 2,097 6.5 1.10 (1.03–1.17) 1.11 (1.04–1.18) 1.09 (1.02–1.16)
50–59 50,826 1,712 5.9 1 (ref.) 1 (ref.) 1 (ref.)
60–69 27,985 1,059 6.7 1.13 (1.04–1.22) 1.04 (0.96–1.12) 1.05 (0.97–1.13)
70–79 11,113 402 6.4 1.08 (0.97–1.20) 0.96 (0.86–1.07) 0.97 (0.87–1.08)
80–89 3,797 177 8.3 1.40 (1.20–1.63) 1.16 (0.99–1.35) 1.17 (1.00–1.36)
90≤ 1,992 80 7.0 1.18 (0.94–1.48) 0.96 (0.76–1.20) 0.98 (0.78–1.22)
p for trend 0.0014 <0.0001 <0.0001
Cardiovascular mortality
<30 1,817 27 2.6 3.24 (2.18–4.83) 2.53 (1.69–3.77) 2.32 (1.55–3.47)
30–39 22,010 150 1.2 1.48 (1.21–1.82) 1.37 (1.11–1.68) 1.29 (1.04–1.59)
40–49 56,703 323 1.0 1.24 (1.05–1.46) 1.22 (1.03–1.45) 1.19 (1.01–1.41)
50–59 50,826 234 0.8 1 (ref.) 1 (ref.) 1 (ref.)
60–69 27,985 158 1.0 1.23 (1.00–1.50) 1.16 (0.94–1.42) 1.17 (0.95–1.43)
70–79 11,113 42 0.7 0.82 (0.59–1.14) 0.76 (0.55–1.06) 0.76 (0.55–1.06)
80–89 3,797 28 1.3 1.62 (1.09–2.39) 1.40 (0.95–2.08) 1.41 (0.95–2.09)
90≤ 1,992 9 0.7 0.97 (0.50–1.89) 0.83 (0.43–1.63) 0.85 (0.44–1.66)
p for trend 0.0005 0.0004 0.0052
Cancer mortality
<30 1,817 50 4.9 1.91 (1.44–2.55) 1.53 (1.15–2.04) 1.50 (1.13–2.01)
30–39 22,010 387 3.1 1.22 (1.08–1.38) 1.15 (1.01–1.30) 1.14 (1.00–1.29)
40–49 56,703 851 2.6 1.04 (0.94–1.14) 1.02 (0.93–1.13) 1.03 (0.93–1.13)
50–59 50,826 737 2.5 1 (ref.) 1 (ref.) 1 (ref.)
60–69 27,985 417 2.6 1.03 (0.91–1.16) 0.97 (0.86–1.09) 0.97 (0.86–1.09)
70–79 11,113 157 2.5 0.98 (0.82–1.16) 0.89 (0.75–1.06) 0.90 (0.76–1.07)
80–89 3,797 62 2.9 1.14 (0.88–1.47) 0.98 (0.76–1.28) 0.98 (0.76–1.27)
90≤ 1,992 28 2.5 0.96 (0.66–1.40) 0.82 (0.56–1.19) 0.81 (0.56–1.19)
p for trend 0.0048 0.0006 0.0013
Other mortality
<30 1,817 70 6.8 2.66 (2.08–3.40) 2.31 (1.81–2.96) 2.07 (1.62–2.65)
30–39 22,010 403 3.2 1.26 (1.12–1.43) 1.28 (1.13–1.44) 1.18 (1.04–1.34)
40–49 56,703 917 2.8 1.11 (1.01–1.23) 1.15 (1.04–1.27) 1.12 (1.01–1.23)
50–59 50,826 738 2.6 1 (ref.) 1 (ref.) 1 (ref.)
60–69 27,985 482 3.0 1.19 (1.06–1.33) 1.07 (0.95–1.20) 1.09 (0.97–1.22)
70–79 11,113 199 3.2 1.24 (1.06–1.45) 1.05 (0.90–1.23) 1.08 (0.92–1.27)
80–89 3,797 87 4.1 1.59 (1.28–1.99) 1.249 (1.00–1.56) 1.27 (1.01–1.58)
90≤ 1,992 43 3.8 1.47 (1.08–2.00) 1.121 (0.82–1.53) 1.17 (0.86–1.59)
p for trend 0.8999 0.0007 0.0940
Myocardial infarction
<30 1,817 75 7.6 2.42 (1.81–3.24) 1.97 (1.47–2.64) 1.97 (1.47–2.65)
30–39 22,010 716 5.9 1.60 (1.41–1.82) 1.45 (1.28–1.65) 1.44 (1.26–1.64)
40–49 56,703 1,434 4.6 1.14 (1.02–1.27) 1.10 (0.99–1.23) 1.10 (0.98–1.22)
50–59 50,826 1,061 3.7 1 (ref.) 1 (ref.) 1 (ref.)
60–69 27,985 511 3.3 0.85 (0.74–0.99) 0.85 (0.73–0.98) 0.85 (0.74–0.98)
70–79 11,113 169 2.7 0.77 (0.62–0.95) 0.77 (0.62–0.95) 0.76 (0.61–0.94)
80–89 3,797 66 3.1 0.93 (0.68–1.29) 0.92 (0.67–1.26) 0.89 (0.65–1.23)
90≤ 1,992 32 2.8 0.79 (0.49–1.26) 0.77 (0.48–1.23) 0.75 (0.47–1.21)
p for trend <0.0001 <0.0001 <0.0001
Stroke
<30 1,817 75 7.5 2.44 (1.92–3.11) 1.93 (1.52–2.46) 1.86 (1.46–2.38)
30–39 22,010 540 4.4 1.43 (1.29–1.60) 1.30 (1.16–1.45) 1.26 (1.12–1.41)
40–49 56,703 1,143 3.6 1.16 (1.06–1.27) 1.12 (1.03–1.23) 1.11 (1.01–1.21)
50–59 50,826 890 3.1 1 (ref.) 1 (ref.) 1 (ref.)
60–69 27,985 498 3.2 1.04 (0.93–1.17) 1.02 (0.91–1.14) 1.03 (0.92–1.15)
70–79 11,113 186 3.0 0.98 (0.83–1.15) 0.96 (0.81–1.13) 0.95 (0.80–1.11)
80–89 3,797 70 3.3 1.12 (0.88–1.43) 1.06 (0.83–1.35) 1.04 (0.82–1.33)
90≤ 1,992 33 2.9 0.99 (0.70–1.41) 0.94 (0.66–1.33) 0.93 (0.66–1.32)
p for trend <0.0001 <0.0001 <0.0001

Model 1: crude; Model 2: adjusted for age, sex, body mass index, alcohol consumption, smoking, regular exercise, and income status; Model 3: model 2 + further adjusted for diabetes mellitus, hypertension, triglycerides, and use of lipid-lowering agents.

HDL-C, high-density lipoprotein cholesterol.

*per 1,000 person-years.